louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06646536: The Effect of Anti-Gravity Treadmill Training in Patients With Meniscus Tears
Official title: The Effect of Anti-Gravity Treadmill Training on Symptoms and Functions in Patients With Meniscus Tears
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Meniscus Tear
Keywords: meniscus
anti-gravity
exercise
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2024-10-17
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the effect of anti-gravity treadmill training on symptoms and functions in patients with meniscus tears.

Detailed description: Meniscus tears are one of the most common sports-related injuries. Acute trauma-related tears are more common in active young individuals and athletes. Symptoms such as pain, effusion, tenderness at the joint line, locking, and knee dysfunction are observed after injury. It is aimed to provide painless movement, normal knee kinematics, and retaining of muscle strength in rehabilitation process. Anti-gravity treadmills use an inflatable space around the lower extremities and significantly reduce body weight during walking and running. Anti-gravity treadmill training protects the joint and surrounding soft tissues against the negative effects of loading during the post-injury recovery process, and allows the tissues to heal safely. The aim of this study is to evaluate the effect of anti-gravity treadmill training on symptoms and functions in patients with meniscus tears.

Patients will be randomly divided into three groups: Anti-Gravity Treadmill Group, Conventional Treadmill Group, and Control Group. All patients will be included physiotherapy and rehabilitation program for 6 weeks, 2 days a week. While subjects in the Anti-Gravity Treadmill Group will participate to training anti-gravity treadmill walking, subjects in the Conventional Treadmill Group will participate walking program on a standard treadmill. Symptoms and functions will be assessed baseline and after 6-week program.

Eligibility criteria: Inclusion Criteria:

* Age between 18-40 years old
* Clinical history and symptoms consistent with MRI-confirmed meniscus tear

Exclusion Criteria:

* History of previous knee surgery
* Other knee ligament pathologies
* Neurological disorders

Primary outcomes:
measure: Visual analog scale-pain
timeFrame: Baseline, 6 weeks
measure: Knee Injury and Osteoarthritis Outcome Score
timeFrame: Baseline, 6 weeks
measure: Dynamic stability
timeFrame: Baseline, 6 weeks
measure: Single leg-hop test
timeFrame: Baseline, 6 weeks
Secondary outcomes:
measure: Western Ontario Meniscal Evaluation Tool
timeFrame: Baseline, 6 weeks
measure: Kinesiophobia
timeFrame: Baseline, 6 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Bezmialem Vakif University
name: Kubra Alpay, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04766736: Netrin-1 & Hepatocellular Carcinoma HCC
Official title: Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: HCC
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Both men and women, between 18 and 85 years of age, suffering from Hepatocellular Carcinoma.

Brief summary: Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.


Eligibility criteria: Inclusion Criteria:

* any patient suffering from HCC
* age \>18
* informed consent provided

Exclusion Criteria:

- absence of informed consent

Primary outcomes:
measure: Netrin-1 expression patterns in HCC samples
timeFrame: Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care.
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hepatogastroenterology service of the Croix-Rousse Hospital
Study officials:
References:
Clinical trial NCT00825136: Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring
Official title: A Study on Mental Health Care by Using Specific Vital Signs
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Panic Disorder
Keywords: Panic Disorder
Temperature Biofeedback
Internet
Lead sponsor: Chimei Medical Center
Sponsor class: OTHER
First posted: 2009-01-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Internet plays a more and more important role in many applications of healthcare. Many researches on the integrations of internet and mental health care have been proposed in recent years. This project aims at the development of an online treatment system which combines the biofeedback therapy and the web technologies to treat the patients suffering from panic disorder with partial response to medications. This project also evaluates the efficacy of a new- designed wireless temperature biofeedback ring.

Detailed description: The participants should be chronic panic patients. They login an web-based server and practice muscle relaxation on-line every day. There will be two two parallel groups: one group practicing muscle relaxation only and the other practicing muscle relaxation with finger surface temperature monitor through a wireless biofeedback ring.

Eligibility criteria: Inclusion Criteria:

1. The participant must fulfill DSM-IV criteria for panic disorder.
2. The participant must be between 18 and 60 years of age.
3. The participant must have panic disorder as the primary problem.
4. If the participant is taking prescribed drugs for panic disorder, a) the dosage have to be constant for 2 months before starting treatment, and b) the participant have to agree to keep the dosage constant for 1 month after starting treatment.
5. If the participant was already in therapy, the contact must have lasted at least 6 months and not be based on cognitive behavior therapy.
6. All participants have access to a computer with an Internet connection.

Exclusion Criteria:

1. The participant suffers from any other psychiatric disorder in immediate need of treatment.
2. The participant fulfills DSM-IV criteria for major depression.
3. The participant has epilepsy, kidney problems, strokes, organic brain syndrome, emphysema, heart disorders, or chronic hypertension. 4. The participant has alcoholism.

Primary outcomes:
measure: score change of The Panic Disorder Severity Scale(PDSS)
timeFrame: day 1 / 4 weeks/ 8 weeks
Secondary outcomes:
measure: score change of MOS 36-Item Short-Form Health Survey (SF-36)
timeFrame: day 1 / 4 weeks/ 8 weeks
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Psychiatry Department, Chimei Medical Center
Study officials:
affiliation: Chimei Medical Center
name: Fong-Lin Jang, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00419536: Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
Official title: A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Hormone Refractory Prostate Cancer Disease
Keywords: LBH
LBH589
Prostate Cancer
HRPC
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-01-08
Enrollment: 108
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.


Eligibility criteria: Inclusion Criteria:

* Patients with hormone refractory prostate cancer
* Patients must have metastatic disease with at least 1 measurable soft tissue lesion that can be assessed by CT or MRI and/or detectable lesion(s) on bone scintigraphy scan. Patients with only elevated PSA levels are not eligible for entry.
* Patients must meet laboratory inclusion criteria defined in the protocol
* Patients must be able to provide written informed consent

Exclusion Criteria:

* Patients with prior or concurrent brain metastases
* Impaired cardiac, gastrointestinal, kidney or liver function
* Use of therapeutic androgens Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: To determine the maximum tolerated dose
Secondary outcomes:
measure: Safety
measure: Tolerability
measure: Biologic activity
measure: Pharmacokinetic profile
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT04073836: GMA and Peri in Moderate-late Preterms
Official title: Early Detection of the Cerebral Palsy in Moderate and Late Preterms Through the General Movements
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Preterm
Assessment
Risk Factor
Cerebral Palsy
Lead sponsor: University of Castilla-La Mancha
Sponsor class: OTHER
First posted: 2019-08-29
Enrollment: 150
Sex: ALL
Minimum age (years): 32
Maximum age (years): 36
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects who were born between the week 32 + 0 days and the week 36 + 6 days

Brief summary: To analyze the relationship between the early diagnosis of cerebral palsy with the risk factors of this pathology in moderate and late premature infants

Detailed description: Analyze a sample of moderate and late premature infants using general movements and verify which of them would have an early diagnosis of cerebral palsy and relate it to their risk factors for this pathology.

Eligibility criteria: Inclusion Criteria:

* Subjects who were born between the week 32 + 0 days and the week 36 + 6 days and who are admitted to the Hospital Nuestra Señora del Prado de Talavera de la Reina or the Hospital Virgen de la Salud de Toledo.

Exclusion Criteria:

* Any type of pre and perinatal diagnostic neurological involvement.
* Any type of pathology associated with prematurity.
* Children who have prescribed any of the following medications (10):

  * Barbiturates
  * Antiepileptic
  * Indomethacin
  * Dexamethasone

Primary outcomes:
measure: gestation weeks
timeFrame: From date of Recruiting until the discharging of neonatal intensive care unit, assessed up to 40 weeks
measure: weight
timeFrame: From date of Recruiting until the discharging of neonatal intensive care unit, assessed up to 40 weeks
measure: size
timeFrame: From date of Recruiting until the discharging of neonatal intensive care unit, assessed up to 40 weeks
measure: cranial perimeter
timeFrame: From date of Recruiting until the discharging of neonatal intensive care unit, assessed up to 40 weeks
measure: Apgar
timeFrame: at birth of each preterm
measure: Magnetic resonance imaging rating scale
timeFrame: From date of Recruiting until the discharging of neonatal intensive care unit, assessed up to 40 weeks
measure: general movements outcome
timeFrame: From date of Recruiting until the discharging of neonatal intensive care unit, assessed up to 40 weeks
measure: PERI outcome
timeFrame: through study completion, an average of 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Toledo
country: Spain
facility: Javier Merino Andrés
Study officials:
References:
Clinical trial NCT05624736: Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Official title: Artificial Intelligence Research of Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Astrocytoma
Glioblastoma Multiforme
Oligodendroglioma
Keywords: Astrocytoma
Glioblastoma
Oligodendroglioma
deep learning
artificial intelligence
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor class: OTHER
First posted: 2022-11-22
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with diagnosis of adult diffuse glioma who recevived tumor rection surgery in our center

Brief summary: This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.

Detailed description: Glioma is a common kind of tumor in central nervous system. The pre-operative prediction of grade, histopathologic type and genotype is important for treatment and management of Adult diffuse Glioma patients. Right now, most of the diagnostic prediction models on glioma are based on 2016 WHO central nervous system tumor guideline. The goal of this study is to establish a new deep learning model to predict Grade, histopathologic type and genotype of adult diffuse Glioma. We will recruit 500 patients with pathologically confirmed diagnosis of Glioblastoma, Astrocytoma and Oligodendroglioma who received neurologic surgery in our center. Each subject underwent pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI. Pathologic diagnosis of each patient are available in pathology department. A deep learning based hierarchical diagnosis

Eligibility criteria: Inclusion Criteria:

1. Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma.
2. Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences
3. No pre-surgery anti-tumor therapy

Exclusion Criteria:

1. Poor image quality
2. Failed image preprocessing
3. Unavailable pathology data

Primary outcomes:
measure: Tumor Grade
timeFrame: up to 2 weeks
measure: Tumor Histologic diagnosis
timeFrame: up to 2 weeks
measure: Tumor genotype
timeFrame: up to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University
state: Jiangsu
Study officials:
References:
Clinical trial NCT00015236: Modeling Impaired Judgement in Cocaine Abusers - 6
Official title: Modeling Impaired Judgement in Cocaine Abusers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cocaine-Related Disorders
Substance-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: New York MDRU
First posted: 2001-04-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: PREVENTION

Brief summary: The purpose of this study is for the modeling of impaired judgement in cocaine abusers.

Detailed description: The objective of this study is to investigate recognition memory and appreciation of changing contingencies in relation to a response judgement.

Eligibility criteria: Inclusion Criteria:

(3 groups)Normal, healthy controls. Recent cocaine experience. Over 6 months since the last cocaine experience.

Exclusion Criteria:

Psychosis or mood disorder. History of seizure, head trauma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York MDRU
state: New York
Study officials:
affiliation: New York MDRU
name: John Rotrosen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: NIDA Research Monograph Series 179, 1998 CPDD 98, 99.
Clinical trial NCT04446936: Comparing Different Surgical Techniques for Coverage of Pressure Ulcer
Official title: A Retrospective Study Comparing Failure and Complications Rates Between Propeller Flap and Random Flap for Pressure Ulcer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pressure Ulcer
Keywords: Ulcer
Flap
Random
Propeller
Paraplegic
Surgery
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-06-25
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with sacral, trochanteric or ischiatic pressure ulcer

Brief summary: The Plastic, Reconstructive and Aesthetic Surgery department of Montpellier was born out of the Wound and Healing department, the first unit of this type to be created in Europe. The investigators quickly became the national leader in the management of pressure ulcers, especially in people with spinal cord injuries.

Our expertise has evolved over time as well as our surgical techniques for covering ulcers, gradually over time the investigators have gone from " random " flaps to " propeller " flaps, more reliable in terms of vascularization and more logical in terms of force distribution and skin tension.

The investigators found subjectively that the rate of complications was lower for the helical flaps. The investigators therefore seek to confirm this trend through a retrospective study on patients operated on in the department between January 1, 2015 and December 31, 2019.


Eligibility criteria: Inclusion criteria:

* Major Patient
* Patient with trochanteric, ischiatic or sacral pressure ulcer
* Patient who undergone flap surgery for pressure ulcer between January 1st, 2015 and December 31st, 2019

Exclusion criteria:

* Other loss of substance than pressure ulcer
* Combined covering with a random flap and a propeller flap
* Surgical revision of a flap without a new flap

Primary outcomes:
measure: Failure rate
timeFrame: 1 day
Secondary outcomes:
measure: Complications rate
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Farid BEKARA, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04431336: Young Patient With Aortic Dissection or Aneurysm: A Prospective Observational Cohort Study
Official title: Clinical Characters, Treatment and Prognosis of the Young Patient With Aortic Dissection or Aneurysm: A Prospective Observational Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Aortic Aneurysm and Dissection
Lead sponsor: Chinese Medical Association
Sponsor class: NETWORK
Collaborators: name: Changhai Hospital
First posted: 2020-06-16
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: young patients aged less than 50 years old and had aortic dissection or aneurysm

Brief summary: Aortic dissection or aneurysm is unusual in young patients, and frequently associated with unusual presentations. However studies about this area is scarce. Besides, the treatment option is not clare. The prognosis of this cohort is also unclear.

The goal of this study was to better understand the characters, treatment option and prognosis of young patient with aortic dissection or aneurysm.

Detailed description: To understand the clinical characteristics, treatment options and prognosis of aortic dissection or aneurysm in young people，the study plan will include young people younger (≤50 years) with aortic dissection or aneurysm from 2020.6. Then collect their clinical data and conduct follow-up studies, in order to understand younger aortic dissection or aneurysm patients.

Eligibility criteria: Inclusion Criteria:

* young patients with aortic dissection or aneurysm

Exclusion Criteria:

* Aortic dissection or aneurysm due to traumatic

Primary outcomes:
measure: Clinical features of young aortic dissection and aneurysm patients
timeFrame: before December 2021
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Vascular surgery, Changhai Hospital
name: Zaiping MD Jing, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Januzzi JL, Isselbacher EM, Fattori R, Cooper JV, Smith DE, Fang J, Eagle KA, Mehta RH, Nienaber CA, Pape LA; International Registry of Aortic Dissection (IRAD). Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol. 2004 Feb 18;43(4):665-9. doi: 10.1016/j.jacc.2003.08.054.